DREAM

Objective

The EvergreenHealth Multiple Sclerosis Center is conducting a randomized, double-blind, placebo-controlled, cross-over trial to assess the safety, tolerability, and efficacy of suvorexant (Belsomra®) in treating insomnia in adults with multiple sclerosis (MS) and fatigue.

Who may be eligible to participate?

Patients 18-75 years of age with a confirmed diagnosis of Multiple Sclerosis and Insomnia Disorder. Patients must be on a stable regimen of disease modifying therapy with no MS exacerbations for 60 days prior to screening.

What does participation involve?

This study will assess whether suvorexant (Belsomra®) is more effective than placebo in treating insomnia and fatigue in people with MS. Enrolled patients will come to the study site for 4 visits (45-90 minutes each) during the study. Patients will also have 3 or more phone conversations with a study coordinator.

Investigator

Theodore Brown, MD, MPH, EvergreenHealth MS Center

Clinical Trial Categories

• Multiple Sclerosis

Contact

EvergreenHealth Research Services at 425-899-5385
or EvergreenResearch@evergreenhealth.com